Skip to main
PCVX

Vaxcyte (PCVX) Stock Forecast & Price Target

Vaxcyte (PCVX) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 75%
Buy 0%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Vaxcyte Inc. has demonstrated a positive outlook supported by an updated peak revenue estimate of $6.8 billion by 2040, reflecting confidence in market adoption for its vaccine candidates. The anticipated launch of VAX-31 in 2028, along with strong Phase 1/2 results, positions the company favorably to capture a significant addressable market, particularly among adults over 50 years old with potential ACIP recommendations. Additionally, positive clinical data from both adult and infant studies of VAX-31 is expected to enhance investor interest and support a favorable stock performance in the near term.

Bears say

Vaxcyte Inc is confronted with significant downside risks, including potential delays in research and development, regulatory hurdles, and lower-than-expected clinical results that could hinder its product pipeline advancements. Recent clinical trial outcomes, particularly the VAX-24 Phase 2 readout, have underwhelmed investors, contributing to a negative perception of the company's prospects in the competitive pediatric vaccine market. Additionally, national vaccine guidelines may not endorse Vaxcyte's products even if they succeed in clinical trials, thereby limiting their commercial viability and potential market uptake.

Vaxcyte (PCVX) has been analyzed by 4 analysts, with a consensus rating of Buy. 75% of analysts recommend a Strong Buy, 0% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Vaxcyte and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Vaxcyte (PCVX) Forecast

Analysts have given Vaxcyte (PCVX) a Buy based on their latest research and market trends.

According to 4 analysts, Vaxcyte (PCVX) has a Buy consensus rating as of Apr 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $88.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $88.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Vaxcyte (PCVX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.